US · PRQR
ProQR Therapeutics N.V.
- Sector
- Healthcare · Biotechnology
- Headquarters
- Leiden 2333 Ck
- Website
- proqr.com
Price · as of 2024-12-31
$1.55
Market cap 167.5M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $92.10 | +5,841.94% |
| Intrinsic Value(DCF) | $40.07 | +2,485.16% |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2010 | |||||
| 2011 | |||||
| 2012 | |||||
| 2013 | |||||
| 2014 | $24.73 | ||||
| 2015 | $4.46 | $477.18 | $626,894.08 | $0.00 | $0.00 |
| 2016 | $5.00 | $30.18 | $0.47 | $0.00 | $126.20 |
| 2017 | $3.40 | $37.39 | $0.00 | $0.00 | $305.10 |
| 2018 | $14.68 | $96.03 | $1.67 | $0.00 | |
| 2019 | $7.95 | $31.99 | $1.19 | $0.00 | $81.00 |
| 2020 | $4.96 | $33.09 | $0.49 | $0.00 | $39.90 |
| 2021 | $0.97 | $33.79 | $0.86 | $0.00 | $0.00 |
| 2022 | $2.86 | $49.51 | $23.91 | $0.00 | $0.00 |
| 2023 | $2.09 | $49.89 | $2,227.34 | $0.00 | $0.00 |
| 2024 | $1.91 | $78.73 | $352,450.92 | $0.00 | $0.00 |
AI valuation
Our deep-learning model estimates ProQR Therapeutics N.V.'s (PRQR) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $92.10
- Current price
- $1.55
- AI upside
- +5,841.94%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$40.07
+2,485.16% upside
Graham-Dodd
—
— upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| PRQR | ProQR Therapeutics N.V. | $1.55 | 167.5M | +4,979% | +2,485% | — | — | -4.80 | 1.50 | 7.05 | -0.05 | — | 1.50 | 100.00% | -161.18% | -146.86% | -41.35% | 56.30% | -17.34% | 0.19 | -28.29 | 3.95 | 3.84 | 5.48 | -286.00% | 19022.00% | -28740.00% | -28.37% | -0.94 | 70.36% | 0.00% | 0.00% | 16.97% | -0.04 | -0.03 | 0.06 | -2.22 |
| ACHV | Achieve Life Sciences, In… | $4.56 | 242.75M | — | — | — | — | -2.53 | 4.82 | — | -2.04 | — | 5.33 | 0.00% | — | — | -409.51% | 2085.90% | -137.33% | 0.48 | -17.92 | 5.46 | 5.14 | 0.07 | -1733.00% | — | 2151.00% | -29.56% | -4.46 | 1589.43% | 0.00% | 0.00% | 3.93% | -1.95 | -2.56 | — | -6.45 |
| ALLO | Allogene Therapeutics, In… | $2.78 | 624.75M | +924% | -60% | — | +3,007% | -1.65 | 1.01 | 19304.10 | -0.92 | — | 1.01 | 100.00% | -1241813.64% | -1170863.64% | -55.13% | -144.12% | -43.24% | 0.21 | -1509.39 | 8.54 | 8.29 | -0.06 | -3684.00% | -7684.00% | -1599.00% | -47.33% | -5.64 | -106.03% | 0.00% | 0.00% | 0.00% | -0.82 | -1.11 | 10135.01 | -3.69 |
| ARCT | Arcturus Therapeutics Hol… | $8.23 | 233.85M | +247% | -10% | — | +29% | -4.85 | 1.63 | 2.84 | -2.38 | -2.89 | 1.63 | 100.00% | -69.13% | -58.49% | -31.16% | -388.69% | -20.93% | 0.12 | — | 4.67 | 3.68 | 2.69 | 16786.00% | -1227.00% | 18760.00% | -15.37% | -0.91 | -245.39% | 0.00% | 0.00% | 0.00% | -1.93 | -3.05 | 1.33 | 0.78 |
| CAPR | Capricor Therapeutics, In… | $27.93 | 1.28B | -15% | -76% | — | -88% | -11.15 | 3.10 | 20.26 | -7.32 | -28.92 | 3.10 | -124.37% | -191.13% | -181.71% | -48.16% | 442.17% | -35.31% | 0.01 | — | 7.77 | 7.70 | 0.24 | 3855.00% | -1155.00% | 5025.00% | -9.21% | -1.90 | 431.47% | 0.00% | 0.00% | 0.00% | -7.07 | -7.25 | 13.52 | 9.49 |
| EDIT | Editas Medicine, Inc. | $2.20 | 214.76M | +883% | +13% | — | +6,172% | -0.60 | 1.05 | 4.38 | 0.40 | -1.40 | 1.05 | 100.00% | -777.22% | -733.72% | -98.10% | 1925.86% | -56.40% | 0.26 | — | 3.75 | 3.71 | 0.41 | 4257.00% | -5864.00% | 6005.00% | -154.71% | -2.72 | 1680.16% | 0.00% | 0.00% | 15.11% | 0.37 | 0.43 | -2.89 | -7.20 |
| IMMP | Immutep Limited | $2.80 | 412.14M | +523% | -76% | — | — | -5.97 | 2.55 | 72.72 | -3.80 | -35.82 | 2.69 | -1117.55% | -2506.49% | -1218.02% | -36.88% | -1019.26% | -34.27% | 0.01 | — | 11.69 | 10.17 | 1.05 | 1667.00% | 3128.00% | 7368.00% | -16.93% | -4.86 | -500.64% | 0.00% | 0.00% | 0.00% | -1.89 | -3.84 | 47.33 | 10.94 |
| MREO | Mereo BioPharma Group plc | $0.37 | 59.17M | +8,875% | — | — | — | -8.52 | 6.04 | — | -7.48 | — | 6.11 | 0.00% | — | — | -77.58% | 2839.57% | -60.54% | 0.11 | -34.56 | 5.40 | 5.28 | 1.55 | -9997.00% | -10000.00% | 5560.00% | -9.10% | -2.37 | 2010.37% | 0.00% | 0.00% | 3.23% | -6.44 | -9.09 | — | 4.76 |
| TRDA | Entrada Therapeutics, Inc… | $11.93 | 455.96M | +114% | -46% | — | +2,115% | -3.36 | 1.58 | 19.01 | -1.67 | — | 1.58 | 83.89% | -621.13% | -565.48% | -39.13% | -244.32% | -31.81% | 0.17 | — | 12.53 | 12.09 | 0.28 | -30655.00% | -8794.00% | 18973.00% | -26.81% | -5.26 | -200.46% | 0.00% | 0.00% | 0.10% | -1.51 | -1.84 | 9.38 | 2.64 |
| VNDA | Vanda Pharmaceuticals Inc… | $8.91 | 526.65M | +158% | -50% | — | — | -2.18 | 1.47 | 2.23 | -1.65 | -0.20 | 2.29 | 93.96% | -69.95% | -102.02% | -50.93% | -119.87% | -38.51% | 0.04 | — | 2.39 | 2.19 | 0.52 | 106875.00% | 872.00% | 57976.00% | -22.94% | -0.75 | -87.57% | 0.00% | 0.00% | 0.00% | -1.52 | -2.08 | 1.07 | 0.57 |
| ZURA | Zura Bio Limited | $6.62 | 430.45M | — | — | — | — | -1.81 | 0.64 | — | 1.48 | — | 0.64 | 0.00% | — | — | -50.84% | 157.33% | -37.38% | 0.00 | — | 9.16 | 9.04 | 3.20 | -7129.00% | — | 2211.00% | -29.76% | -1.44 | 80.25% | 0.00% | 0.00% | 81.08% | 1.48 | 2.91 | — | 1.74 |
About ProQR Therapeutics N.V.
ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. It primarily develops sepofarsen that is in phase II/III clinical trial illuminate trial for treating leber congenital amaurosis 10 disease; and ultevursen, which is in phase II/III clinical trial to treat USH2A-mediated retinitis pigmentosa and usher syndrome. The company also engages in the developing of Axiomer RNA base-editing platform technology. It has a license agreement with Radboud University Medical Center, Inserm Transfert SA, Ionis Pharmaceuticals, Inc., and Leiden University Medical Center, as well as license and research collaboration with Eli Lilly and Company for the discovery, development, and commercialization of potential new medicines for genetic disorders in the liver and nervous system. ProQR Therapeutics N.V. was incorporated in 2012 and is headquartered in Leiden, the Netherlands.
- CEO
- Daniel Anton de Boer
- Employees
- 166
- Beta
- 0.20
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($40.07 ÷ $1.55) − 1 = +2,485.16% (DCF, example).